Impact Factor
4.06
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
5.32
2,254 total citations
h5-index
51
h5 depth signal
Cited share
76.6%
338 of 441
Total citations
2,254
Citation footprint
Metric signal
4.90
External metric anchor
Self-citation
6.4%
144 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
751
China
563
United Kingdom
422
Canada
295
Australia
278
Citing Fields of Research
Osteopathies
2,791
Musculoskeletal Disorders
783
Nutrition & Dietetics
201
Endocrinology & Metabolism
97
Postural Control
94
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
9,457
Articles tracked across the journal lifetime
Indexed publication set
441
338 cited publications
Last 12 months
350
29.2 publications/month
Open access share
32.9%
115 OA publications in the last year
Leading citing country
United States
751 citing publications
Leading citing field
Osteopathies
2,791 citing publications
Latest tracked publication
19 October 2026
10 recent records available
Coverage & Indexing History
v1n1,Oct. 1990-
v1n1,Oct. 1990-
Active Coverage
Research Focus & Classification
Indexed Subjects
Osteopathies
Issuing & Sponsoring Bodies
Contributor
European Foundation for Osteoporosis
Contributor
National Osteoporosis Foundation
Contributor
International Osteoporosis Foundation
Broad Categories
Metabolism
Orthopedics
Osteopathies
MeSH Descriptors
Osteoporosis
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1007/s00198-026-08265-2
Open DOI
Circumstances of fall-related fracture events among men in late life
02
DOI 10.1007/s00198-026-08273-2
Open DOI
Osteopenia in adolescent idiopathic scoliosis
03
DOI 10.1007/s00198-026-08260-7
Open DOI
Response to the Letter to the Editor on “Interpreting romosozumab-associated BMD changes in osteogenesis imperfecta: design, densitometry, and multiplicity”
We respond to methodological questions raised in a “Letter to the Editor” regarding our retrospective case series on romosozumab treatment in osteogenesis imperfecta (OI). We clarify that the retrospective study design, the rarity of the...
04
05
DOI 10.1007/s00198-026-08252-7
Open DOI
Building bone in the jaw with denosumab in adult Langerhans cell histiocytosis
06
07
08
DOI 10.1007/s00198-026-08227-8
Open DOI
Prevalence of hypophosphatasia in general and selected patient populations: a systematic review
09
10
Bibliographical & Catalog Notes
Title from cover.
Also issued online.
Vols. for 1999- issued by International Osteoporosis Foundation and the National Osteoporosis Foundation of the USA.
Vol. 1, no. 1 (OCT 1990)19901015 Notice published Printed on acid-free paper